跳至主要内容
临床试验/NCT00002546
NCT00002546已完成3 期

A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus

Gynecologic Oncology Group65 个研究点 分布在 1 个国家目标入组 216 人开始时间: 1993年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
216
试验地点
65

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy is more effective than combination chemotherapy in treating patients with cancer of the uterus.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to combination chemotherapy in treating patients with cancer of the uterus.

详细描述

OBJECTIVES:

  • Compare the survival, progression-free interval, and failure patterns in patients with optimally debulked stage I-IV carcinosarcoma of the uterus treated with whole abdominal radiotherapy vs ifosfamide and cisplatin.
  • Compare the incidence and type of acute and late adverse events observed with these treatment regimens in this patient population.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive whole abdominal radiotherapy 5 days a week for 4 weeks, followed by radiotherapy boost to the pelvis 5 days a week for 2.2 weeks.
  • Arm II: Patients receive cisplatin IV followed by ifosfamide IV over 1 hour on days 1-4. Treatment continues every 3 weeks for 3 courses.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

年龄范围
21 Years 至 120 Years(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Histologically confirmed primary homologous or heterologous carcinosarcoma of the uterus (corpus and cervix)
  • •Surgical stage I-IV disease, including positive adnexa, tumor invading the serosa, positive pelvic and/or para-aortic nodes, involvement of the mucosa of the bowel, bladder, or rectum, intra-abdominal metastases, positive pelvic washings, or vaginal involvement within planned radiation port
  • •Prior total abdominal hysterectomy with bilateral salpingo-oophorectomy and maximum tumor resection of all gross intra-abdominal/pelvic disease, including grossly involved pelvic and para-aortic nodes within 8 weeks before study
  • •No greater than 1 cm residual disease
  • •Cervical sarcomas also allowed
  • •No metastasis beyond the abdominal cavity at diagnosis, including the following:
  • •Parenchymal liver metastasis
  • •Lung metastasis
  • •Positive inguinal lymph nodes
  • •Positive scalene nodes
  • •Radiographic or pathologic evidence of bone or brain metastasis
  • •PATIENT CHARACTERISTICS:
  • •21 and over
  • •Performance status:
  • •Hematopoietic:
  • •WBC at least 3,000/mm3
  • •Granulocyte count at least 1,500/mm3
  • •Platelet count at least 100,000/mm3
  • •Bilirubin no greater than 1.5 times normal
  • •SGOT no greater than 3 times normal
  • •Albumin at least 3 g/dL
  • •No acute hepatitis
  • •Creatinine no greater than 1.5 mg/dL OR
  • •Creatinine clearance at least 50 mL/min
  • •No septicemia
  • •No severe infection
  • •No severe gastrointestinal bleeding
  • •No prior invasive or concurrent malignancy within the past 5 years except nonmelanoma skin cancer
  • •PRIOR CONCURRENT THERAPY:
  • •Biologic therapy:
  • •Not specified
  • •Chemotherapy:
  • •No prior chemotherapy
  • •Endocrine therapy:
  • •Prior hormonal therapy allowed
  • •Radiotherapy:
  • •See Disease Characteristics
  • •No prior radiotherapy
  • •See Disease Characteristics
  • •No prior therapy that would preclude study therapy

排除标准

  • 未提供

研究者

申办方类型
Network

研究点 (65)

Loading locations...

相似试验